Dyslipidemia in insulin resistance: clinical challenges and adipocentric therapeutic frontiers

References

• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA285(19), 2486–2497 (2001).
   Google Scholar
• Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med.339, 229–234 (1998).
   PubMed Web of Science ®Google Scholar
• Hu FB, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of Type 2 diabetes. Diabetes Care25(7), 1129–1134 (2002).
   PubMed Web of Science ®Google Scholar
• Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care25(7), 1177–1184 (2002).
   PubMed Web of Science ®Google Scholar
• Bierman EL. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler. Thromb.12(6), 647–656 (1992).
   PubMed Web of Science ®Google Scholar
• Krauss RM, Siri PW. Dyslipidemia in Type 2 diabetes. Med. Clin. North Am.88(4), 897–909 (2004).
   PubMed Web of Science ®Google Scholar
• Barter PJ, Ballantyne CM, Carmena R et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J. Intern. Med.259(3), 247–258 (2006).
   PubMed Web of Science ®Google Scholar
• Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J. Clin. Invest.115(5), 1111–1119 (2005).
   PubMed Web of Science ®Google Scholar
• Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest.112(12), 1796–1808 (2003).
   PubMed Web of Science ®Google Scholar
• Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest.112(12), 1821–1830 (2003).
   PubMed Web of Science ®Google Scholar
• Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J. Clin. Invest.95(1), 158–166 (1995).
   PubMed Web of Science ®Google Scholar
• Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes31, 217–225 (1982).
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Carlson MG, Nurjhan N. Fat metabolism in human obesity. Am. J. Physiol.266(4 Pt 1), E600–E605 (1994).
   PubMedGoogle Scholar
• Malmstrom R, Packard CJ, Caslake M et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia40(4), 454–462 (1997).
   PubMedGoogle Scholar
• Fisher EA, Ginsberg HN. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J. Biol. Chem.277(20), 17377–17380 (2002).
   PubMed Web of Science ®Google Scholar
• Avramoglu RK, Qiu W, Adeli K. Mechanisms of metabolic dyslipidemia in insulin resistant states: deregulation of hepatic and intestinal lipoprotein secretion. Front. Biosci.8, d464–d476 (2003).
   Google Scholar
• Sniderman AD, Cianflone K. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler. Thromb.13(5), 629–636 (1993).
   PubMedGoogle Scholar
• Yao Z, McLeod RS. Synthesis and secretion of hepatic apolipoprotein B-containing lipoproteins. Biochim. Biophys. Acta1212(2), 152–166 (1994).
   PubMedGoogle Scholar
• Yao Z, Tran K, McLeod RS. Intracellular degradation of newly synthesized apolipoprotein B. J. Lipid Res.38(10), 1937–1953 (1997).
   PubMed Web of Science ®Google Scholar
• Gordon DA, Jamil H. Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly. Biochim. Biophys. Acta1486(1), 72–83 (2000).
   PubMed Web of Science ®Google Scholar
• Sparks JD, Sparks CE. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim. Biophys. Acta1215(1–2), 9–32 (1994).
   PubMedGoogle Scholar
• Au WS, Kung HF, Lin MC. Regulation of microsomal triglyceride transfer protein gene by insulin in HepG2 cells: roles of MAPKerk and MAPKp38. Diabetes52(5), 1073–1080 (2003).
   PubMed Web of Science ®Google Scholar
• Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr. Opin. Lipidol.12(3), 297–304 (2001).
   PubMed Web of Science ®Google Scholar
• Fredenrich A. Role of apolipoprotein CIII in triglyceride-rich lipoprotein metabolism. Diabetes Metab.24(6), 490–495 (1998).
   PubMed Web of Science ®Google Scholar
• Chen M, Breslow JL, Li W, Leff T. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J. Lipid Res.35(11), 1918–1924 (1994).
   PubMed Web of Science ®Google Scholar
• Duvillard L, Pont F, Florentin E et al. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur. J. Clin. Invest.30(8), 685–694 (2000).
   PubMed Web of Science ®Google Scholar
• Chan DC, Nguyen MN, Watts GF, Barrett PH. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein b and high-density lipoprotein apolipoprotein A-I metabolism. J. Clin. Endocrinol. Metab.93(2), 557–564 (2008).
   PubMed Web of Science ®Google Scholar
• Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N. Engl. J. Med.320(16), 1060–1068 (1989).
   PubMed Web of Science ®Google Scholar
• Despres JP, Couillard C, Gagnon J et al. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. Arterioscler. Thromb. Vasc. Biol.20(8), 1932–1938 (2000).
   PubMed Web of Science ®Google Scholar
• Carr MC, Ayyobi AF, Murdoch SJ, Deeb SS, Brunzell JD. Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler. Thromb. Vasc. Biol.22(4), 667–673 (2002).
   PubMed Web of Science ®Google Scholar
• Rashid S, Uffelman KD, Lewis GF. The mechanism of HDL lowering in hypertriglyceridemic, insulin- resistant states. J. Diabetes Complications16(1), 24–28 (2002).
   PubMed Web of Science ®Google Scholar
• Lewis GF, Murdoch S, Uffelman K et al. Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone. Diabetes53(11), 2893–2900 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis173(1), 1–12 (2004).
   PubMed Web of Science ®Google Scholar
• Arai T, Yamashita S, Hirano K et al. Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler. Thromb.14(7), 1129–1136 (1994).
   PubMedGoogle Scholar
• Dullaart RP, Sluiter WJ, Dikkeschei LD, Hoogenberg K, Van Tol A. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur. J. Clin. Invest.24(3), 188–194 (1994).
   PubMed Web of Science ®Google Scholar
• Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res.96(12), 1221–1232 (2005).
   PubMed Web of Science ®Google Scholar
• Rashid S, Barrett PH, Uffelman KD et al. Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler. Thromb. Vasc. Biol.22(3), 483–487 (2002).
   PubMed Web of Science ®Google Scholar
• Badellino KO, Wolfe ML, Reilly MP, Rader DJ. Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med.3(2), e22 (2006).
   PubMed Web of Science ®Google Scholar
• Jaye M, Lynch KJ, Krawiec J et al. A novel endothelial-derived lipase that modulates HDL metabolism. Nat. Genet.21, 424–428 (1999).
   PubMed Web of Science ®Google Scholar
• Ishida T, Choi S, Kundu RK et al. Endothelial lipase is a major determinant of HDL level. J. Clin. Invest.111(3), 347–355 (2003).
   PubMed Web of Science ®Google Scholar
• Maugeais C, Tietge UJ, Broedl UC et al. Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase. Circulation108(17), 2121–2126 (2003).
   PubMed Web of Science ®Google Scholar
• Jin W, Millar JS, Broedl U, Glick JM, Rader DJ. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J. Clin. Invest.111(3), 357–362 (2003).
   PubMed Web of Science ®Google Scholar
• Ma K, Cilingiroglu M, Otvos JD et al. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc. Natl Acad. Sci. USA100(5), 2748–2753 (2003).
   PubMed Web of Science ®Google Scholar
• deLemos AS, Wolfe ML, Long CJ, Sivapackianathan R, Rader DJ. Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation106(11), 1321–1326 (2002).
   PubMed Web of Science ®Google Scholar
• Standards of medical care in diabetes. Diabetes Care28(Suppl. 1), S4–S36 (2005).
   PubMed Web of Science ®Google Scholar
• Management of dyslipidemia in adults with diabetes. Diabetes Care23(Suppl. 1), S57–S60 (2000).
   PubMedGoogle Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation110(2), 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Stern MP, Mitchell BD, Haffner SM, Hazuda HP. Does glycemic control of type II diabetes suffice to control diabetic dyslipidemia? A community perspective. Diabetes Care15(5), 638–644 (1992).
   PubMed Web of Science ®Google Scholar
• Jacobs MJ KT, Pio JR, Malik S, L’Italien GJ, Chen RS, Wong ND. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res. Clin. Pract.70(3), 263–269 (2005).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study), case-control study. Lancet364 (9438), 937–952 (2004).
   PubMed Web of Science ®Google Scholar
• Garvey WT, Kwon S, Zheng D et al. Effects of insulin resistance and Type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes52(2), 453–462 (2003).
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J. Cardiovasc. Risk.7(5), 325–331 (2000).
   PubMedGoogle Scholar
• Cannon CP. Combination therapy in the management of mixed dyslipidaemia. J. Intern. Med.263(4), 353–365 (2008).
   PubMed Web of Science ®Google Scholar
• Ali YS, Linton MF, Fazio S. Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia. Curr. Opin. Endocrinol. Diabetes Obes.15(2), 142–146 (2008).
   PubMedGoogle Scholar
• Glassberg H, Rader DJ. Management of lipids in the prevention of cardiovascular events. Annu. Rev. Med.59, 79–94 (2008).
   PubMed Web of Science ®Google Scholar
• Standards of medical care in diabetes – 2007. Diabetes Care30(Suppl. 1), S4–S41 (2007).
   PubMedGoogle Scholar
• Goldberg IJ, Merkel M. Lipoprotein lipase: physiology, biochemistry, and molecular biology. Front. Biosci.6: D388–405 (2001).
   Web of Science ®Google Scholar
• Bamba V, Rader DJ. Obesity and atherogenic dyslipidemia. Gastroenterology132(6), 2181–2190 (2007).
   PubMed Web of Science ®Google Scholar
• Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J. Lipid Res.43(12), 1997–2006 (2002).
   PubMed Web of Science ®Google Scholar
• Ruge T, Svensson M, Eriksson JW, Olivecrona G. Tissue-specific regulation of lipoprotein lipase in humans: effects of fasting. Eur. J. Clin. Invest.35(3), 194–200 (2005).
   PubMed Web of Science ®Google Scholar
• Large V, Peroni O, Letexier D, Ray H, Beylot M. Metabolism of lipids in human white adipocyte. Diabetes Metab.30(4), 294–309 (2004).
   PubMed Web of Science ®Google Scholar
• Millar JS. Acyl CoA: Diacylglycerol acyltransferases (DGATs) as therapeutic targets for cardiovascular disease. In: Lipid And Atherosclerosis. Packard C, Rader D (Eds). Taylor and Fraser Group (2006).
   Google Scholar
• Haemmerle G, Zimmermann R, Zechner R. Letting lipids go: hormone-sensitive lipase. Curr. Opin. Lipidol.14(3), 289–297 (2003).
   PubMed Web of Science ®Google Scholar
• Langin D. Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. Pharmacol. Res.53(6), 482–491 (2006).
   PubMed Web of Science ®Google Scholar
• Tunaru S, Kero J, Schaub A et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med.9(3), 352–355 (2003).
   PubMed Web of Science ®Google Scholar
• Offermanns S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol. Sci.27(7), 384–390 (2006).
   PubMed Web of Science ®Google Scholar
• Taggart AK, Kero J, Gan X et al. (D)-β-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J. Biol. Chem.280(29), 26649–26652 (2005).
   PubMed Web of Science ®Google Scholar
• Bays HE, Gonzalez-Campoy JM, Bray GA et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev. Cardiovasc. Ther.6(3), 343–368 (2008).
   PubMedGoogle Scholar
• Bays H, Rodbard HW, Schorr AB, Gonzalez-Campoy JM. Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk. Curr. Treat. Options Cardiovasc. Med.9(4), 259–271 (2007).
   PubMedGoogle Scholar
• Yu YH, Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ. Res.96(10), 1042–1052 (2005).
   PubMed Web of Science ®Google Scholar
• Panarotto D, Remillard P, Bouffard L, Maheux P. Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue-specific manner. Eur. J. Clin. Invest.32(2), 84–92 (2002).
   PubMedGoogle Scholar
• Boden G. Free fatty acids (FFA), a link between obesity and insulin resistance. Front. Biosci.3, d169–d175 (1998).
   PubMedGoogle Scholar
• Skowronski R, Hollenbeck CB, Varasteh BB, Chen YD, Reaven GM. Regulation of non-esterified fatty acid and glycerol concentration by insulin in normal individuals and patients with Type 2 diabetes. Diabet. Med.8(4), 330–333 (1991).
   PubMed Web of Science ®Google Scholar
• Wise A, Foord SM, Fraser NJ et al. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem.278(11), 9869–9874 (2003).
   PubMed Web of Science ®Google Scholar
• Karpe F, Frayn KN. The nicotinic acid receptor – a new mechanism for an old drug. Lancet363 (9424), 1892–1894 (2004).
   PubMed Web of Science ®Google Scholar
• Pike NB, Wise A. Identification of a nicotinic acid receptor: is this the molecular target for the oldest lipid-lowering drug? Curr. Opin. Investig. Drugs5(3), 271–275 (2004).
   PubMedGoogle Scholar
• Morrow JD, Awad JA, Oates JA, Roberts LJ, 2nd. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J. Invest. Dermatol.98(5), 812–815 (1992).
   PubMed Web of Science ®Google Scholar
• van Herk T, Brussee J, van den Nieuwendijk AM et al. Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J. Med. Chem.46(18), 3945–3951 (2003).
   PubMed Web of Science ®Google Scholar
• Lai E, Wenning LA, Crumley TM et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D(2) receptor antagonist. Clin. Pharmacol. Ther. (2007).
   Google Scholar
• Paolini JF, Mitchel YB, Reyes R et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am. J. Cardiol.101(5), 625–630 (2008).
   PubMed Web of Science ®Google Scholar
• Daval M, Diot-Dupuy F, Bazin R et al. Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J. Biol. Chem.280(26), 25250–25257 (2005).
   PubMed Web of Science ®Google Scholar
• Towler MC HD. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res.100(3), 328–341 (2007).
   PubMed Web of Science ®Google Scholar
• Brooks BJ, Arch JR, Newsholme EA. Effect of some hormones on the rate of the triacylglycerol/fatty-acid substrate cycle in adipose tissue of the mouse in vivo. Biosci Rep.3(3), 263–267 (1983).
   PubMed Web of Science ®Google Scholar
• Hardie DG, Carling D. The AMP-activated protein kinase – fuel gauge of the mammalian cell? Eur. J. Biochem.246(2), 259–273 (1997).
   PubMedGoogle Scholar
• Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med.8(11), 1288–1295 (2002).
   PubMed Web of Science ®Google Scholar
• Wu X, Motoshima H, Mahadev K et al. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes52(6), 1355–1363 (2003).
   PubMed Web of Science ®Google Scholar
• Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Adipokines and treatment with niacin. Metabolism55(10), 1283–1285 (2006).
   PubMed Web of Science ®Google Scholar
• Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res.37(5), 907–925 (1996).
   PubMed Web of Science ®Google Scholar
• Li P, Zhu Z, Lu Y, Granneman JG. Metabolic and cellular plasticity in white adipose tissue II: role of peroxisome proliferator-activated receptor-alpha. Am. J. Physiol. Endocrinol. Metab.289(4), E617–E626 (2005).
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med.351(11), 1106–1118 (2004).
   PubMed Web of Science ®Google Scholar
• Bensaid M, Gary-Bobo M, Esclangon A et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol.63(4), 908–914 (2003).
   PubMed Web of Science ®Google Scholar
• Moller DE, Berger JP. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int. J. Obes. Relat. Metab. Disord.27(Suppl. 3), S17–S21 (2003).
   PubMed Web of Science ®Google Scholar
• Szapary PO, Bloedon LT, Samaha FF et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler. Thromb. Vasc. Biol.26(1), 182–188 (2006).
   PubMed Web of Science ®Google Scholar
• Trujillo ME, Scherer PE. Adiponectin – journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J. Intern. Med.257(2), 167–175 (2005).
   PubMed Web of Science ®Google Scholar
• Combs TP, Pajvani UB, Berg AH et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology145(1), 367–383 (2004).
   PubMed Web of Science ®Google Scholar
• Iwaki M, Matsuda M, Maeda N et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes52(7), 1655–1663 (2003).
   PubMed Web of Science ®Google Scholar
• Saha AK, Avilucea PR, Ye JM et al. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo.Biochem. Biophys Res Commun.314(2), 580–585 (2004).
   PubMed Web of Science ®Google Scholar
• Duffy D, Rader D. Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity. Trends Cardiovasc. Med.17(2), 35–43 (2007).
   PubMed Web of Science ®Google Scholar
• Osei-Hyiaman D, Harvey-White J, Batkai S, Kunos G. The role of the endocannabinoid system in the control of energy homeostasis. Int. J. Obes. (Lond.)30(Suppl. 1), S33–S38 (2006).
   Web of Science ®Google Scholar
• Samaha FF, Szapary PO, Iqbal N et al. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol.26(3), 624–630 (2006).
   PubMed Web of Science ®Google Scholar
• Lenman A, Fowler CJ. Interaction of ligands for the peroxisome proliferator-activated receptor γ with the endocannabinoid system. Br. J. Pharmacol.151(8), 1343–1351 (2007).
   PubMed Web of Science ®Google Scholar
• Yu YH, Ginsberg HN. The role of acyl-CoA:diacylglycerol acyltransferase (DGAT) in energy metabolism. Ann. Med.36(4), 252–261 (2004).
   PubMed Web of Science ®Google Scholar
• Bagnato C, Igal RA. Overexpression of diacylglycerol acyltransferase-1 reduces phospholipid synthesis, proliferation, and invasiveness in simian virus 40-transformed human lung fibroblasts. J. Biol. Chem.278(52), 52203–52211 (2003).
   PubMed Web of Science ®Google Scholar
• Smith SJ, Cases S, Jensen DR et al. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nat. Genet.25(1), 87–90 (2000).
   PubMed Web of Science ®Google Scholar
• Chen HC, Smith SJ, Ladha Z et al. Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. J. Clin. Invest.109(8), 1049–1055 (2002).
   PubMed Web of Science ®Google Scholar
• Stone SJ, Myers HM, Watkins SM et al. Lipopenia and skin barrier abnormalities in Dgat2-deficient mice. J. Biol. Chem.279(12), 11767–11776 (2004).
   PubMed Web of Science ®Google Scholar
• Oelkers P, Behari A, Cromley D, Billheimer JT, Sturley SL. Characterization of two human genes encoding acyl coenzyme A:cholesterol acyltransferase-related enzymes. J. Biol. Chem.273(41), 26765–26771 (1998).
   PubMed Web of Science ®Google Scholar
• Cases S, Stone SJ, Zhou P et al. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J. Biol. Chem.276(42), 38870–38876 (2001).
   PubMed Web of Science ®Google Scholar
• Meegalla RL, Billheimer JT, Cheng D. Concerted elevation of acyl-coenzyme A:diacylglycerol acyltransferase (DGAT) activity through independent stimulation of mRNA expression of DGAT1 and DGAT2 by carbohydrate and insulin. Biochem. Biophys. Res. Commun.298(3), 317–323 (2002).
   PubMed Web of Science ®Google Scholar
• Yen CL, Monetti M, Burri BJ, Farese RV Jr. The triacylglycerol synthesis enzyme DGAT1 also catalyzes the synthesis of diacylglycerols, waxes, and retinyl esters. J. Lipid Res.46(7), 1502–1511 (2005).
   PubMed Web of Science ®Google Scholar
• Orland MD, Anwar K, Cromley D et al. Acyl coenzyme A dependent retinol esterification by acyl coenzyme A: diacylglycerol acyltransferase 1. Biochim. Biophys. Acta1737(1), 76–82 (2005).
   PubMed Web of Science ®Google Scholar
• Chen HC, Farese RV, Jr. DGAT and triglyceride synthesis: a new target for obesity treatment? Trends Cardiovasc. Med.10(5), 188–192 (2000).
   PubMed Web of Science ®Google Scholar
• Yu XX, Murray SF, Pandey SK et al. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology42(2), 362–371 (2005).
   PubMed Web of Science ®Google Scholar
• Dean N. Pharmacology of 2´-O-(2-methoxy)-ethyl-modified antisense oligonucleotide. In: Antisense Drug Technology: Principles, Strategies and Applications. Crooke ST (Ed.). NY, USA, 319–338 (2001).
   Google Scholar
• Liu Y, Millar JS, Cromley DA et al. Knockdown of Acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and apoB secretion in mice. Biochim. Biophys. Acta (2008).
   Google Scholar
• Phillips DI, Caddy S, Ilic V et al. Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. Metabolism45(8), 947–950 (1996).
   PubMed Web of Science ®Google Scholar
• Ebeling P, Essen-Gustavsson B, Tuominen JA, Koivisto VA. Intramuscular triglyceride content is increased in IDDM. Diabetologia41(1), 111–115 (1998).
   PubMed Web of Science ®Google Scholar
• Manco M, Mingrone G, Greco AV et al. Insulin resistance directly correlates with increased saturated fatty acids in skeletal muscle triglycerides. Metabolism49(2), 220–224 (2000).
   PubMed Web of Science ®Google Scholar
• Russell AP. Lipotoxicity: the obese and endurance-trained paradox. Int. J. Obes. Relat. Metab. Disord.28(Suppl. 4), S66–S71 (2004).
   Google Scholar
• Schenk S, Cook JN, Kaufman AE, Horowitz JF. Postexercise insulin sensitivity is not impaired after an overnight lipid infusion. Am. J. Physiol. Endocrinol. Metab.288(3), E519–E525 (2005).
   Google Scholar
• Goodpaster BH, He J, Watkins S, Kelley DE. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J. Clin. Endocrinol. Metab.86(12), 5755–5761 (2001).
   PubMed Web of Science ®Google Scholar
• Boden G. Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and Type 2 diabetes. Exp. Clin. Endocrinol. Diabetes111(3), 121–124 (2003).
   PubMed Web of Science ®Google Scholar
• Ellis BA, Poynten A, Lowy AJ et al. Long-chain acyl–CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am. J. Physiol. Endocrinol. Metab.279(3), E554–E560 (2000).
   Google Scholar
• Lee JS, Pinnamaneni SK, Eo SJ et al. Saturated, but not n-6 polyunsaturated, fatty acids induce insulin resistance: role of intramuscular accumulation of lipid metabolites. J. Appl. Physiol.100(5), 1467–1474 (2006).
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang Y, Chen N et al. Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance. J. Clin. Invest.117(6), 1679–1689 (2007).
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in Type 2 diabetic patients. J. Clin. Endocrinol. Metab.87(6), 2784–2791 (2002).
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Mahankali A, Wajcberg E et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in Type 2 diabetic patients. J. Clin. Endocrinol. Metab.89(9), 4312–4319 (2004).
   PubMed Web of Science ®Google Scholar
• Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med.355(22), 2297–2307 (2006).
   PubMed Web of Science ®Google Scholar
• Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ. Res.95(9), 858–866 (2004).
   PubMed Web of Science ®Google Scholar
• Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Natl Acad. Sci. USA100(12), 7265–7270 (2003).
   PubMed Web of Science ®Google Scholar
• Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT), implication of macrophages resident in the AT. J. Clin. Endocrinol. Metab.90(4), 2282–2289 (2005).
   PubMed Web of Science ®Google Scholar
• Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature394, 894–897 (1998).
   PubMed Web of Science ®Google Scholar
• Gu L, Okada Y, Clinton SK et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell. Biol.2, 275–281 (1998).
   Google Scholar
• Weisberg SP, Hunter D, Huber R et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest.116(1), 115–124 (2006).
   PubMed Web of Science ®Google Scholar
• Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G et al. Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology211(6–8), 487–501 (2006).
   PubMed Web of Science ®Google Scholar
• Porcheray F, Viaud S, Rimaniol AC et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin. Exp. Immunol.142(3), 481–489 (2005).
   PubMed Web of Science ®Google Scholar
• Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol.3(1), 23–35 (2003).
   PubMed Web of Science ®Google Scholar
• Cullen JP, Morrow D, Jin Y et al. Resveratrol inhibits expression and binding activity of the monocyte chemotactic protein-1 receptor, CCR2, on THP-1 monocytes. Atherosclerosis195(1), e125–e133 (2007).
   PubMedGoogle Scholar
• Ahn J, Lee H, Kim S, Ha T. Resveratrol inhibits TNF-α-induced changes of adipokines in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun.364(4), 972–977 (2007).
   PubMed Web of Science ®Google Scholar
• Das S, Das DK. Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Patents Cardiovasc. Drug Discov.2(2), 133–138 (2007).
   PubMedGoogle Scholar
• Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest.117(1), 175–184 (2007).
   PubMed Web of Science ®Google Scholar
• Bouhlel MA, Derudas B, Rigamonti E et al. PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab.6(2), 137–143 (2007).
   PubMed Web of Science ®Google Scholar
• Han KH, Chang MK, Boullier A et al. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor γ. J. Clin. Invest.106(6), 793–802 (2000).
   PubMed Web of Science ®Google Scholar
• Barlic J, Zhang Y, Foley JF, Murphy PM. Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor γ-dependent pathway. Circulation114(8), 807–819 (2006).
   PubMed Web of Science ®Google Scholar
• Charo IF. Macrophage polarization and insulin resistance: PPARγ in control. Cell Metab.6(2), 96–98 (2007).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med.356(24), 2457–2471 (2007).
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA298(10), 1180–1188 (2007).
   PubMed Web of Science ®Google Scholar
• Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes47(4), 507–514 (1998).
   PubMed Web of Science ®Google Scholar